BRIEF-Bristol Myers Squibb Completes Acquisition Of Karuna Therapeutics, Strengthening Neuroscience Portfolio

Reuters03-18

March 18 (Reuters) - Bristol-Myers Squibb Co :

* BRISTOL MYERS SQUIBB COMPLETES ACQUISITION OF KARUNA THERAPEUTICS, STRENGTHENING NEUROSCIENCE PORTFOLIO

* BRISTOL-MYERS SQUIBB CO: TRANSACTION TO RESULT IN ABOUT $12 BILLION ONE-TIME, NON-DEDUCTIBLE ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT CHARGE

* BRISTOL-MYERS SQUIBB CO: ACQUIRED IPR&D CHARGE TO IMPACT BOTH 2024 Q1 AND FULL-YEAR GAAP AND NON-GAAP EPS BY ABOUT $5.93

Source text for Eikon: Further company coverage:

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2420479120?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-03-18 21:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2420479120","market":"us","top_or_hot":-1,"title":"BRIEF-Bristol Myers Squibb Completes Acquisition Of Karuna Therapeutics, Strengthening Neuroscience Portfolio","media":"Reuters","content":"<html><body><p>March 18 (Reuters) - Bristol-Myers Squibb Co   :</p><p>   * BRISTOL MYERS SQUIBB COMPLETES ACQUISITION OF KARUNA THERAPEUTICS, STRENGTHENING NEUROSCIENCE PORTFOLIO</p><p>   * BRISTOL-MYERS SQUIBB CO: TRANSACTION TO RESULT IN ABOUT $12 BILLION ONE-TIME, NON-DEDUCTIBLE ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT CHARGE</p><p>   * BRISTOL-MYERS SQUIBB CO: ACQUIRED IPR&amp;D CHARGE TO IMPACT BOTH 2024 Q1 AND FULL-YEAR GAAP AND NON-GAAP EPS BY ABOUT $5.93</p><p>Source text for Eikon:    Further company coverage:   </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Bristol Myers Squibb Completes Acquisition Of Karuna Therapeutics, Strengthening Neuroscience Portfolio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Bristol Myers Squibb Completes Acquisition Of Karuna Therapeutics, Strengthening Neuroscience Portfolio\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-18 21:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>March 18 (Reuters) - Bristol-Myers Squibb Co   :   * BRISTOL MYERS SQUIBB COMPLETES ACQUISITION OF KARUNA THERAPEUTICS, STRENGTHENING NEUROSCIENCE PORTFOLIO   * BRISTOL-MYERS SQUIBB CO: TRANSACTION TO...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4559","symbol_name":"巴菲特持仓","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2420479120","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2420479120","pubTimestamp":1710767575,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"March 18  - Bristol-Myers Squibb Co   :   * BRISTOL MYERS SQUIBB COMPLETES ACQUISITION OF KARUNA THERAPEUTICS, STRENGTHENING NEUROSCIENCE PORTFOLIO   * BRISTOL-MYERS SQUIBB CO: TRANSACTION TO RESULT IN ABOUT $12 BILLION ONE-TIME, NON-DEDUCTIBLE ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT CHARGE   * BRISTOL-MYERS SQUIBB CO: ACQUIRED IPR&D CHARGE TO IMPACT BOTH 2024 Q1 AND FULL-YEAR GAAP AND NON-GAAP EPS BY ABOUT $5.93Source text for Eikon:    Further company coverage:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4559":"巴菲特持仓","BK4588":"碎股","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","KRTX":"Karuna Therapeutics","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","BMY":"施贵宝","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","BK4581":"高盛持仓","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4126":"金属与玻璃容器","BK4532":"文艺复兴科技持仓","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","MYE":"Myers Industries Inc","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4534":"瑞士信贷持仓","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU0237698245.USD":"富达环球地产基金A","BK4585":"ETF&股票定投概念","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","BK4139":"生物科技","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4007":"制药","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BK4535":"淡马锡持仓"},"translate_title":"Bristol Myers Squibb完成对Karuna Therapeutics的收购，加强神经科学产品组合","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYE":1,"KRTX":1,"BMY":1},"content_text":"March 18 (Reuters) - Bristol-Myers Squibb Co   :   * BRISTOL MYERS SQUIBB COMPLETES ACQUISITION OF KARUNA THERAPEUTICS, STRENGTHENING NEUROSCIENCE PORTFOLIO   * BRISTOL-MYERS SQUIBB CO: TRANSACTION TO RESULT IN ABOUT $12 BILLION ONE-TIME, NON-DEDUCTIBLE ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT CHARGE   * BRISTOL-MYERS SQUIBB CO: ACQUIRED IPR&D CHARGE TO IMPACT BOTH 2024 Q1 AND FULL-YEAR GAAP AND NON-GAAP EPS BY ABOUT $5.93Source text for Eikon:    Further company coverage:","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2420479120"}